ABBV-466

N/A

Report date: 2026/02/13 20:01:31

Base Information

Drug NameABBV-466
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionInterleukin-23 subunit p19 inhibitorsIntegrin alpha-4/beta-7 antagonists
TargetsInterleukin-23 subunit p19Integrin alpha-4/beta-7
Therapy Area/IndicationsCrohn Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes RisankizumabTrosunilimab
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesN/A
Active IndicationsCrohn Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A